Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,501–1,600 of 10,906
Pregeljc, D., Skok, J., Seravalli, T. V., Mencin, N., Krušič, A., Ličen, J., Nemec, K. Š., Štrancar, A., & Sekirnik, R. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28299 · Cited by 59
SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines
Singh, D. D., Parveen, A., & Yadav, D. K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.777212 · Cited by 58
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
Huang, K.-Y. A., Chen, X., Mohapatra, A., Nguyen, H. T. V., Schimanski, L. M., Tan, T. K., Rijal, P., Vester, S. K., Hills, R. A., Howarth, M. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35949-8 · Cited by 52
Pang, A. P. S., Higgins‐Chen, A., Comite, F., Raica, I., Arboleda, C., Went, H., Mendez, T. L., Schotsaert, M., Dwaraka, V. B., Smith, R. C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.819749 · Cited by 76
Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
Kraft, J. C., Pham, M. N., Shehata, L., Brinkkemper, M., Boyoglu-Barnum, S., Sprouse, K. R., Walls, A. C., Cheng, S., Murphy, M., Pettie, D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100780 · Cited by 63
Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery
Sanchez, A. J. D. S., Zhao, K., Huayamares, S. G., Hatit, M. Z. C., Lokugamage, M. P., Loughrey, D., Dobrowolski, C. N., Wang, S., Kim, H., Paunovska, K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.037 · Cited by 55
Monitoring Serum Spike Protein with Disposable Photonic Biosensors Following SARS-CoV-2 Vaccination
Cognetti, J. S., & Miller, B. L. (2021) · Sensors · doi:10.3390/s21175857 · Cited by 53
Ioannou, G. N., Locke, E. R., Green, P. K., & Berry, K. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101326 · Cited by 58
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 60
Huang, C., Duan, X., Wang, J., Tian, Q., Ren, Y., Chen, K., Zhang, Z., Li, Y., Feng, Y., Zhong, K., et al. (2022) · Advanced Science · doi:10.1002/advs.202205532 · Cited by 63
Zerbo, O., Ray, G. T., FIREMAN, B. H., Layefsky, E., Goddard, K., Lewis, E. M., Ross, P., Omer, S. B., Greenberg, M., & Klein, N. P. (2023) · Nature Communications · doi:10.1038/s41467-023-36547-4 · Cited by 56
Seirafianpour, F., Pourriyahi, H., Mesgarha, M. G., Mohammad, A. P., Shaka, Z., & Goodarzi, A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15461 · Cited by 51
Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 64
Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis
Murali, M., Gumber, L., Jethwa, H., Ganesh, D., Hartmann‐Boyce, J., Sood, H. S., Zaccardi, F., & Khunti, K. (2023) · BMC Medicine · doi:10.1186/s12916-023-02809-7 · Cited by 59
Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection
Karim, S. S. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00468-2 · Cited by 52
Dendrimer-Mediated Delivery of DNA and RNA Vaccines
Kisakova, L. A., Apartsin, E. K., Nizolenko, L. F., & Карпенко, Л. И. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041106 · Cited by 55
Self-assembling protein nanoparticles for cytosolic delivery of nucleic acids and proteins
Eweje, F., Ibrahim, V., Shajii, A., Walsh, M. L., Ahmad, K., Alrefai, A., Miyasato, D. L., Davis, J. R., Ham, H. O., Li, K., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02664-2 · Cited by 67
O'Shea, D. G., Curtin, C. M., & O’Brien, F. J. (2022) · Biomaterials Science · doi:10.1039/d1bm01540k · Cited by 65
Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering
Mukalel, A. J., Hamilton, A. G., Billingsley, M. M., Li, J. J., Thatte, A. S., Han, X., Safford, H. C., Padilla, M. S., Papp, T. E., Parhiz, H., et al. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312038 · Cited by 64
Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components
Wu, F., Li, N., Xiao, Y., Palanki, R., Yamagata, H. M., Mitchell, M. J., & Han, X. (2025) · Small Methods · doi:10.1002/smtd.202401632 · Cited by 73
Lee, S. W., Moon, J., Lee, S.-K., Lee, H. J., Moon, S., Chung, S. J., Yeo, Y., Park, T. S., Park, D. W., Kim, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.779212 · Cited by 53
Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain
Iguacel, I., Maldonado, A. L., Ruíz-Cabello, A. L., Casaus, M., Moreno, L. A., & Martínez‐Jarreta, B. (2021) · Vaccines · doi:10.3390/vaccines9111321 · Cited by 52
Watanabe, A., Yasuhara, J., Iwagami, M., Miyamoto, Y., Yamada, Y., Suzuki, Y., Takagi, H., & Kuno, T. (2022) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2022.3456 · Cited by 57
Gill, L. A., & Jones, C. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004367 · Cited by 51
The Power of Field-Flow Fractionation in Characterization of Nanoparticles in Drug Delivery
Bian, J., Gobalasingham, N. S., Purchel, A. A., & Lin, J. (2023) · Molecules · doi:10.3390/molecules28104169 · Cited by 58
Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications
Vadovics, M., Zhao, W., Daley, E. F., Lam, K., Daly, O. M., Rashid, K., Lee, H. R., Schreiner, P., Lundgreen, K. A., Gaudette, B. T., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01958-5 · Cited by 68
“Pfizer/BioNTech’s BNT162b2 and Moderna’s mRNA-1273 are highly effective in preventing COVID-19-associated hospital admissions and deaths by eliciting potent antigen-specific neutralizing antibody and T cell responses 1–4 .”
Mechanisms of antibody-dependent enhancement of infectious disease
Wells, T. J., Esposito, T., Henderson, I. R., & Labzin, L. I. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01067-9 · Cited by 71
He, Y., Zhang, W., Xiao, Q., Fan, L., Huang, D., Chen, W., & He, W. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.11.002 · Cited by 77
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G., Lighter, J., Elbel, B. D., Troxel, A. B., & Heguy, A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152702 · Cited by 56
Ali, G. G. M. N., Rahman, M. M., Hossain, M. A., Rahman, M. S., Paul, K. C., Thill, J., & Samuel, J. (2021) · Healthcare · doi:10.3390/healthcare9091110 · Cited by 56
Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
Ghimire, D., Han, Y., & Lu, M. (2022) · Viruses · doi:10.3390/v14061255 · Cited by 45
Underrepresentation of older adults in clinical trials on COVID-19 vaccines: A systematic review
Veronese, N., Petrović, M., Bénétos, A., Denkinger, M. D., Guðmundsson, A., Knol, W., Marking, C., Soulis, G., Maggi, S., & Cherubini, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101455 · Cited by 60
Liu, Y., Liu, Q., Zhang, B., Chen, S., Shen, Y., Li, Z., Zhang, J., Yang, Y., Li, M., & Wang, Y. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01373-0 · Cited by 66
“In addition, the recent regulatory approvals of mRNA-based vaccines for COVID-19 and respiratory syncytial virus further validate the future translational applicability of such approaches in clinical settings for treating AIDs and other diseases 29,57 .”
Grieco, T., Maddalena, P., Sernicola, A., Muharremi, R., Basili, S., Alvaro, D., Cangemi, R., Rossi, A., & Pellacani, G. (2021) · Dermatologic Therapy · doi:10.1111/dth.15153 · Cited by 52
“January 6, 2021, January 29, 2021 and March 11, 2021, respectively.(2,3) Vaccination schedules involve a single dose for COVID-19 Vaccine Janssen and two doses administered via intramuscular route for the other vaccines; the interval between doses is 21 days for ComirnatyTM, 28 days for SpikevaxTM, and 12 weeks for Va…”
BackgroundThe Complex Association between COPD and COVID-19
Awatade, N. T., Wark, P. A. B., Chan, A. S. L., Mamun, S. A. A., Esa, N. Y. M., Matsunaga, K., Rhee, C. K., Hansbro, P. M., Sohal, S. S., & on behalf of the Asian Pacific Society of Respirology (APSR) COPD Assembly (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113791 · Cited by 64
Acute Myocardial Infarction Within 24 Hours After COVID-19 Vaccination
Sung, J. G., Sobieszczyk, P. S., & Bhatt, D. L. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.06.047 · Cited by 56
Teran, R. A., Walblay, K., Shane, E. L., Xydis, S. N., Gretsch, S. R., Gagner, A., Samala, U., Choi, H., Zelinski, C., & Black, S. R. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16634 · Cited by 51
van Doremalen, N., Purushotham, J. N., Schulz, J. E., Holbrook, M. G., Bushmaker, T., Carmody, A., Port, J. R., Yinda, C. K., Okumura, A., Saturday, G. A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.09.426058 · Cited by 50
Yang, Y., Cai, Z., & Zhang, J. (2021) · Bioscience Reports · doi:10.1042/bsr20203584 · Cited by 65
Shrestha, S., Khatri, J., Shakya, S., Danekhu, K., Khatiwada, A. P., Sah, R., Bhuvan, K. C., Paudyal, V., Khanal, S., & Rodriguez-Morales, A. J. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00852-z · Cited by 56
Urbanowicz, R. A., Tsoleridis, T., Jackson, H. J., Cusin, L., Duncan, J. D., Chappell, J. G., Tarr, A. W., Nightingale, J., Norrish, A. R., Ikram, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj0847 · Cited by 49
Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data
Pei, D. (2025) · ACS Nano · doi:10.1021/acsnano.5c11721 · Cited by 80
(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43
Design Strategies for and Stability of mRNA–Lipid Nanoparticle COVID-19 Vaccines
Liu, T., Tian, Y., Zheng, A., & Cui, C. (2022) · Polymers · doi:10.3390/polym14194195 · Cited by 59
Bošnjak, B., Odak, I., Barros‐Martins, J., Sandrock, I., Hammerschmidt, S. I., Permanyer, M., Patzer, G. E., Georgiev, H., Jauregui, R. G., Tscherne, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772240 · Cited by 53
Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids
Numata, M., & Voelker, D. R. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159139 · Cited by 57
Hybrid core-shell particles for mRNA systemic delivery
Andretto, V., Repellin, M., Pujol, M., Almouazen, E., Sidi‐Boumedine, J., Granjon, T., Zhang, H., Remaut, K., Jordheim, L. P., Briançon, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.042 · Cited by 55
Zickler, A. M., Liang, X., Gupta, D., Mamand, D. R., Luca, M. D., Corso, G., Errichelli, L., Hean, J., Sen, T., Elsharkasy, O. M., et al. (2024) · Advanced Science · doi:10.1002/advs.202407619 · Cited by 67
Self-citationHamilton, A. G., Swingle, K. L., Thatte, A. S., Mukalel, A. J., Safford, H. C., Billingsley, M. M., El-Mayta, R. D., Han, X., Nachod, B. E., Joseph, R. A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01171 · Cited by 66
Vaccine adjuvants for infectious disease in the clinic
Goetz, M. J., Thotathil, N., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10663 · Cited by 67
Bagacean, C., Letestu, R., Al‐Nawakil, C., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006215 · Cited by 51
Intelligent Biomaterialomics: Molecular Design, Manufacturing, and Biomedical Applications
Yi, Y., An, H., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202305099 · Cited by 53
Abbasi, S., Matsui-Masai, M., Yasui, F., Hayashi, A., Tockary, T. A., Mochida, Y., Akinaga, S., Kohara, M., Kataoka, K., & Uchida, S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.022 · Cited by 61
Nel, A. E., & Miller, J. F. (2021) · ACS Nano · doi:10.1021/acsnano.1c01845 · Cited by 51
Self-citationCOVID-19 complications in males and females: recent developments
Chaturvedi, R., Lui, B., Aaronson, J. A., White, R. S., & Samuels, J. D. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0027 · Cited by 59
Nasal vaccines: solutions for respiratory infectious diseases
Nakahashi-Ouchida, R., Fujihashi, K., Kurashima, Y., Yuki, Y., & Kiyono, H. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.10.009 · Cited by 57
An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
Yang, L., Chen, X., Wang, K., Li, L., & Zhang, H. (2024) · Vaccines · doi:10.3390/vaccines12070727 · Cited by 57
Chemical engineering of CRISPR–Cas systems for therapeutic application
Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O’Reilly, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01086-0 · Cited by 65
“The most common method for RNA-based delivery is using LNPs, as previously demonstrated by clinically approved siRNA therapeutics 133 and mRNA vaccines 134,135 .”
A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination
Canney, M., Atiquzzaman, M., Cunningham, A., Zheng, Y., Lee, E., Hawken, S., Zhao, Y.-S., & Barbour, S. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022030258 · Cited by 43
Björk, J., Inghammar, M., Moghaddassi, M., Rasmussen, M., Malmqvist, U., & Kahn, F. (2022) · Infectious Diseases · doi:10.1080/23744235.2021.1982144 · Cited by 51
Murase, K. (2022) · Toxins · doi:10.3390/toxins14020078 · Cited by 65
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells
Hafezi, B., Chan, L., Knapp, J. P., Karimi, N., Alizadeh, K., Mehrani, Y., Bridle, B. W., & Karimi, K. (2021) · Cells · doi:10.3390/cells10071761 · Cited by 56
COVID‐19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later
Ekpanyapong, S., Bunchorntavakul, C., & Reddy, K. R. (2021) · Journal of Viral Hepatitis · doi:10.1111/jvh.13590 · Cited by 53
Current evidence for COVID-19 therapies: a systematic literature review
Welte, T., Ambrose, L., Sibbring, G. C., Sheikh, S., Müllerová, H., & Sabir, I. N. (2021) · European Respiratory Review · doi:10.1183/16000617.0384-2020 · Cited by 49
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19
Casey, J. D., Beskow, L. M., Brown, J., Brown, S. M., Gayat, É., Gong, M. N., Harhay, M. O., Jaber, S., Jentzer, J. C., Laterre, P., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00044-3 · Cited by 61
Deb, A., Abdelmalek, J., IWUJI, K. C., & NUGENT, K. M. (2021) · Journal of Primary Care & Community Health · doi:10.1177/21501327211029230 · Cited by 52
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino-Urdaniz, I. M., Steiner, P. J., Kirby, M. B., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Leonard, A. C., Peng, L., Sprenger, K. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109627 · Cited by 49
mRNA vaccine designs for optimal adjuvanticity and delivery
Mochida, Y., & Uchida, S. (2024) · RNA Biology · doi:10.1080/15476286.2024.2333123 · Cited by 63
Li, P., Liu, Y., Cheng, Z., Yu, X., & Li, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113568 · Cited by 62
Butler, M., Tamborska, A., Wood, G. K., Ellul, M. A., Thomas, R. H., Galea, I., Pett, S. L., Singh, B., Solomon, T., Pollak, T. A., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326924 · Cited by 57
Cavanna, L., Citterio, C., Biasini, C., Madaro, S., Bacchetta, N., Lis, A., Cremona, G., Muroni, M., Bernuzzi, P., Cascio, G. L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.035 · Cited by 53
Liu, C., Lee, J., Ta, C. N., Soroush, A., Rogers, J. R., Kim, J. H., Natarajan, K., Zucker, J. E., & Weng, C.-H. (2021) · medRxiv · doi:10.1101/2021.10.05.21264583 · Cited by 32
Mandolesi, M., Sheward, D. J., Hanke, L., Ma, J., Pushparaj, P., Perez Vidakovics, L., Kim, C., Àdori, M., Lenart, K., Loré, K., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100252 · Cited by 50
High‐Precision Synthesis of RNA‐Loaded Lipid Nanoparticles for Biomedical Applications
Seo, H., Jeon, L., Kwon, J., & Lee, H. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202203033 · Cited by 54
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, M. K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
Vaccine efficacy and iron deficiency: an intertwined pair?
Drakesmith, H., Pasricha, S.-R., Cabantchik, I., Hershko, C., Weiss, G., Girelli, D., Stoffel, N. U., Muckenthaler, M. U., Nemeth, E., Camaschella, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00201-5 · Cited by 60
Parks, K. R., Moodie, Z., Allen, M., Yen, C., Furch, B. D., MacPhee, K. J., Ozorowski, G., Heptinstall, J., Hahn, W. O., Zheng, Z., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6831 · Cited by 61
Self-citationDurability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsPreprint
Pegu, A., O’Connell, S. E., Schmidt, S. D., O'Dell, S. J., Talana, C. A., Lai, L., Albert, J., Anderson, E. J., Bennett, H., Corbett, K. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.13.444010 · Cited by 50
Self-citationAn Update on mRNA-Based Viral Vaccines
Jeeva, S., Kim, K., Shin, C. H., Wang, B., & Kang, S. (2021) · Vaccines · doi:10.3390/vaccines9090965 · Cited by 54
Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M. G., Johnson, M. P., Roellinger, D. L., Vanichkachorn, G., Huskins, W. C., & Swift, M. D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab926 · Cited by 58
Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00295-5 · Cited by 58
Self-citationRegan, A. K., Arah, O. A., Fell, D. B., & Sullivan, S. G. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab626 · Cited by 53
Genome-scale CRISPR screens identify host factors that promote human coronavirus infection
Grodzki, M., Bluhm, A. P., Schaefer, M., Tagmount, A., Russo, M., Sobh, A., Rafiee, R., Vulpe, C. D., Karst, S. M., & Norris, M. H. (2022) · Genome Medicine · doi:10.1186/s13073-022-01013-1 · Cited by 58
COVID-19 vaccines in pregnancy
Nunes, M. C., & Madhi, S. A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.012 · Cited by 54
mRNA vaccines in the prevention and treatment of diseases
Gu, Y., Duan, J., Yang, N., Yang, Y., & Zhao, X. (2022) · MedComm · doi:10.1002/mco2.167 · Cited by 58
A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine
Murvelashvili, N., & Tessnow, A. H. (2021) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/23247096211043386 · Cited by 52
Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study
Shoukat, A., VILCHES, T. N., Moghadas, S. M., Sah, P., Schneider, E. C., Shaff, J., Zucker, J. R., Quinn, C., Chokshi, D. A., & Galvani, A. P. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100085 · Cited by 61
Brisotto, G., Muraro, E., Montico, M., Corso, C., Evangelista, C., Casarotto, M., Caffau, C., Vettori, R., Cozzi, M. R., Zanussi, S., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.035 · Cited by 57
Pitzalis, M., Idda, M. L., Lodde, V., Loizedda, A., Lobina, M., Żołędziewska, M., Virdis, F., Delogu, G., Pirinu, F., Marini, M. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.781843 · Cited by 55
Oliver, M. J., Thomas, D., Balamchi, S., Ip, J., Naylor, K. L., Dixon, S. N., McArthur, E., Kwong, J. C., Perl, J., Atiquzzaman, M., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091262 · Cited by 50
Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 55
COVID-19 Vaccines and Autoimmune Hematologic Disorders
Mingot‐Castellano, M. E., Butta, N. V., Canaro, M., Solano, M. D. C. G. D. C., Sánchez‐González, B., Jiménez‐Bárcenas, R., Pascual, C., Caballero‐Navarro, G., Ureña, L. E., González‐López, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10060961 · Cited by 49
Mirtaleb, M. S., Falak, R., Heshmatnia, J., Bakhshandeh, B., Taheri, R. A., Soleimanjahi, H., & Emameh, R. Z. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109934 · Cited by 65
Liu, H., Pietersz, G. A., Peter, K., & Wang, X. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01279-y · Cited by 60
Current Vaccine Platforms in Enhancing T-Cell Response
Ura, T., Takeuchi, M., Kawagoe, T., Mizuki, N., Okuda, K., & Shimada, M. (2022) · Vaccines · doi:10.3390/vaccines10081367 · Cited by 60
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Expert review on global real-world vaccine effectiveness against SARS-CoV-2
Chuenkitmongkol, S., Solante, R., Burhan, E., Chariyalertsak, S., Chiu, N., Dung, D. V., Husin, M., Hwang, K., Kiertiburanakul, S., Kulkarni, P. S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2092472 · Cited by 53
Caronna, E., van den Hoek, T. C., Bolay, H., García‐Azorín, D., Gago‐Veiga, A. B., Valeriani, M., Takizawa, T., Meßlinger, K., Shapiro, R. E., Goadsby, P. J., et al. (2023) · Cephalalgia · doi:10.1177/03331024221131337 · Cited by 49
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.